文献速递白血病

CD19阴性表达与RUNX1-RUNX1T1阳性儿童AML无复发生存期较差相关:JPLSG AML-05研究结果

Negative CD19 expression is associated with inferior relapse-free survival in children with RUNX1-RUNX1T1-positive acute myeloid leukaemia: results from the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
PubMed 文献 · Br J Haematol · 2019-06-27

该回顾性分析纳入JPLSG AML-05方案中100例RUNX1-RUNX1T1阳性儿童急性髓系白血病患者,分析白血病表面抗原表达与基因组数据以确定复发危险因素。

要点

  • CD19阳性与阴性RUNX1-RUNX1T1 AML患者间的生物学差异有待进一步研究。

研究设计与样本

  • 对JPLSG AML-05方案入组的100例RUNX1-RUNX1T1阳性儿童AML患者进行回顾性分析,分析白血病表面抗原表达与基因组数据以确定复发危险因素。

关键数值与推荐

  • CD19阴性组n=59,KIT外显子17突变组n=21,总样本100例。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We performed a retrospective analysis of leukaemic surface antigen expression and genomic data from a total of 100 RUNX1-RUNX1T1-positive paediatric acute myeloid leukaemia (AML) patients enrolled in the Japanese Paediatric Leukaemia/Lymphoma Study Group (JPLSG) AML-05 protocol to determine risk factors for relapse. In univariate analysis, the KIT exon 17 mutation (n = 21) and CD19 negativity (n = 59) were significant risk factors for relapse (P = 0·01). In multivariate analysis, CD19 negativity was the sole significant risk factor for relapse (hazard ratio, 3·09; 95% confidence interval, 1·26-7·59; P < 0·01), suggesting that biological differences between CD19-positive and CD19-negative RUNX1-RUNX1T1 AML patients should be investigated.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Sakamoto K, Shiba N, Deguchi T, et al. Negative CD19 expression is associated with inferior relapse-free survival in children with RUNX1-RUNX1T1-positive acute myeloid leukaemia: results from the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study. Br J Haematol. 2019. PMID: 31247675. doi:10.1111/bjh.16080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。